CliffBio
small molecule

OXYTROL FOR WOMEN

OXYBUTYNIN

Loss of exclusivity—loss of exclusivity
CompanyAbbVie Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameOXYTROL FOR WOMEN
Active ingredientOXYBUTYNIN
Strength3.9MG/24HR
Dosage formFILM, EXTENDED RELEASE
RouteTRANSDERMAL
ModalitySmall molecule
FDA approvalJanuary 2013
Marketing statusOTC

More from AbbVie Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

OXYTROL FOR WOMEN patent cliff — loss of exclusivity — | CliffBio